Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | PDE2A | O00408 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34468797 | 0.90 | KDM4E (0.62) | EGLN1KDM4ESMYD3POLBKMT2A | |
| SCHEMBL34468812 | 0.90 | KDM4E (0.62) | EGLN1KDM4ESMYD3POLBKMT2A | |
| SCHEMBL34468866 | 0.90 | KDM4E (0.62) | EGLN1KDM4ESMYD3POLBKMT2A | |
| SCHEMBL34468937 | 0.86 | PADI4 (0.57) | EGLN1KDM4ESMYD3NPC1PDE2A | |
| SCHEMBL34468746 | 0.86 | KDM4E (0.51) | EGLN1KDM4ESMYD3POLBKMT2A | |
| SCHEMBL1440740 | 0.82 | SMYD3 (0.57) | KDM4ESMYD3MAOAKMT2ACCR1 | |
| SCHEMBL16627755 | 0.79 | MAOA (0.57) | KDM4ESMYD3NPC1MAOAKMT2A | |
| SCHEMBL34468835 | 0.78 | ALDH1A1 (0.54) | KDM4ESMYD3POLBGAAKMT2A | |
| SCHEMBL34468772 | 0.78 | SMYD3 (0.49) | KDM4ESMYD3GAACCR1ALDH1A1 | |
| SCHEMBL34468764 | 0.78 | SMYD3 (0.56) | KDM4ESMYD3POLBGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090571-A1 | APYRASE INHIBITORS | TEXAS CROP SCIENCE, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260116873-A1 | APYRASE INHIBITORS | TEXAS CROP SCIENCE INC (US) | 2026-04-30 | — | — | US | claimed |
| WO-2026090571-A1 | APYRASE INHIBITORS | TEXAS CROP SCIENCE, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260116873-A1 | APYRASE INHIBITORS | TEXAS CROP SCIENCE INC (US) | 2026-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116873-A1 | APYRASE INHIBITORS | APEH, AP3M1, SRR | EGLN1 2195/4885KDM4E 2360/4885SMYD3 1625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.